Literature DB >> 27039996

[The shades of anti-Jo1 positive antisynthetase syndrome in a Hungarian cohort].

Katalin Szabó1, Melinda Nagy-Vincze1, Levente Bodoki1, Katalin Hodosi1, Katalin Dankó1, Zoltán Griger1.   

Abstract

INTRODUCTION: In idiopathic inflammatory myopathies, the presence of anti-Jo-1 antibody defines a distinct clinical phenotype (myositis, arthritis, interstitial lung disease, Raynaud's phenomenon fever, mechanic's hands), called antisynthetase syndrome. AIM: To determine the demographic data as well as clinical, laboratory and terapeutical features of anti-Jo1 positive patients, followed by the department of the authors.
METHOD: The medical records of 49 consecutive anti-Jo1 patients were reviewed.
RESULTS: Demographic and clinical results were very similar to those published by other centers. Significant correlation was found between the anti-Jo-1 titer and the creatine kinase and C-reactive protein levels. Distinct laboratory results measured at the time of diagnosis of the disease (C-reactive protein, antigen A associated with Sjogren's syndrome, positive rheumatoid factor), and the presence of certain clinical symptoms (fever, vasculitic skin) may indicate a worse prognosis within the antisyntetase positive patient group.
CONCLUSION: In the cases above more agressive immunosuppressive therapy may be required.

Entities:  

Keywords:  anti-Jo-1; anti-Jo1; antisynthetase syndrome; antiszintetáz-szindróma; dermatomyositis; polymyositis

Mesh:

Substances:

Year:  2016        PMID: 27039996     DOI: 10.1556/650.2016.30400

Source DB:  PubMed          Journal:  Orv Hetil        ISSN: 0030-6002            Impact factor:   0.540


  1 in total

1.  Effect of Genetic and Laboratory Findings on Clinical Course of Antisynthetase Syndrome in a Hungarian Cohort.

Authors:  Katalin Szabó; Levente Bodoki; Melinda Nagy-Vincze; Anett Vincze; Erika Zilahi; Peter Szodoray; Katalin Dankó; Zoltán Griger
Journal:  Biomed Res Int       Date:  2018-10-25       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.